Clear Search

Showing 1 result for “Silk ME” published 2018.

October 2021

Baricitinib for Lupus Erythematosus: A Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial

Lancet 2018;392:222–31

This international Phase 2 study aimed to assess the efficacy and safety of baricitinib, an oral JAK-1 and -2 inhibitor, in patients with SLE who were not adequately controlled despite standard background therapy.

more…